Veatonite diet drug Belviq helps people lose weight and stay long-term

recently, research has shown that Eisai'scompany, a weight-loss drug, Belviq, can help people lose weight and maintain it for a long time without increasing the risk of heart diseasefindings were published in the Prestigious Medical Journal of New England (NEJM)Belviq
Belviq is an FDAof the(approved weight loss drug, which was originally approved in 2012 for adult patients with a body mass index (BMI) of 30 or higher (obese) or a BMI of 27 or higher (overweight) and with weight-related complications (such as high blood pressure, abnormal blood lipid abnormalities, type 2 diabetes, etc.)Belviq is a type of serotonin 2C (5-HT2c) receptor agonist that can agitate the 5-HT2c receptor located on the POMC nerve of the hypothalamus, thus achieving an appetite-suppressing effect and increasing energy consumptionBelviq is the first weight-loss drug to complete a long-term heart safety study required by the FDAthe study
in camelLIA-TIMI 61, a post-release study of the results, researchers recruited 12,000 obese or overweight subjects with atherosclerosis cardiovascular disease or a variety of cardiovascular risk factorsThe subjects took Belviq (10 mg) or a placebo twice a day and were guided by lifestyle and dietary recommendationsresults showed that the number of subjects who had achieved at least 5% weight loss after one year was 1986 (38.7%) in the Belviq group and 883 (17.4%) in the placebo group (advantage ratio 3.01; 95% (CI), 2.74 - 3.30; P 0.001)Compared to patients in the Belviq group, heart risk factors (including blood pressure, heart rate, blood sugar control and blood lipids) had a slight advantagethe main safety outcome rate in the Belviq group was 2.0% per year (median follow-up time 3.3 years) and the placebo group had 2.1% (risk ratio, 0.99; 95% ci, 0.85 - 1.14; P 0.001), the extended major cardiovascular events were 4.1% and 4.2% per annum, respectively.PAdverse events of particular interest were not common, and the incidence of the two groups was similar The Belviq group had 13 patients with severe hypoglycemia, 4 higher than those in the comfort group (P - 0.04) The proportion of subjects with diabetes in the Belviq group was lower, at 8.5%, compared with 10.3% in the placebo group the researchers also tested 3,270 participants for heart valve damage (but found no significant differences between the Belviq group and the placebo group) There were 21 in the Belviq group and 11 in the placebo group who had suicidal thoughts or behaviors, but given their history of depression and a very small percentage, these events may have been accidental these results show that long-term treatment using Belviq does not increase the incidence of MACE, which refers to the incidence of death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese patients at high risk of cardiovascular events But while Belviq did not increase the risk of heart disease, it did not reduce the risk of heart disease as many would like